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Many solid tumors, including non-small cell lung cancers
(NSCLCs), are characterized by heterogenous expres-
sion of p53 protein in the neoplastic cells. To analyse the
molecular implications of this finding, we examined
topographic distribution of p53 mutations using in situ
polymerase chain reaction (PCR) in primary NSCLCs,
showing distinct patterns of variable p53 overexpression
by immunohistochemistry. Unique sets of primers for
each mutation were designed, and optimal PCR
conditions were determined by standard PCR using
DNA from cloned mutants or cell lines established from
these tumors. All tumor cell nuclei, regardless of the
status of p53 overexpression, demonstrated homogeneous
distribution of mutant p53 with specific primers,
indicating that only subgroups of the mutated cells
overexpressed p53 protein. In situ reverse transcription
(RT) –PCR was applied to detect mutant mRNA in the
individual tumor cells using specific primers. We found
that in each case the distribution of mutant p53 mRNA
coincided with that of immunohistochemical overexpres-
sion of p53 protein. Our results suggest that the
regulation of mutant p53 expression, but not the
genotype, is heterogeneous in the neoplastic cells. The
topographic genomapping of p53 in NSCLC using in situ
PCR provides a novel approach to view molecular
mechanisms of lung carcinogenesis. Oncogene (2001)
20, 2579 – 2586.
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Introduction
Alterations in the tumor suppressor gene p53 are
frequent events in non-small cell lung cancers
(NSCLC), and may have prognostic importance
(Takahashi et al., 1989; Mitsudomi et al., 1992; Horio
et al., 1993). The main mechanism of action involves a
point mutation in one allele and complete loss of the
second allele (Greenblatt et al., 1994).
Mutant p53 has a longer half-life than wild p53 (Oren
et al., 1981; Reihsaus et al., 1990) and we have previously
established a correlation with the overexpression of p53
protein by immunohistochemistry and the presence of
mutations in lung cancer cell lines (Bodner et al., 1992).
In lung tumors, we noted marked variability in the
immunohistochemical staining patterns of p53 protein
with two major patterns (Ebina et al., 1994). One
revealed focal positivity throughout the tumor at
random locations giving a spotty appearance, and
another consisted of positive staining along the periphery
of the tumor. Interestingly, there was no correlation
between the expression of p53 and proliferating cell
nuclear antigen (PCNA) in the tumors, suggesting that
the variability was perhaps not due to cell cycle
dependent regulation (Prives, 1998).
There are two likely explanations for the hetero-
geneous distribution patterns of p53 immunoreactivity in
tumors: (i) polyclonal expansion of the tumor cells with
dierent p53 status, or (ii) dierences in the regulation of
mutant p53 expression through transcriptional activity
or stability in tumor cells while they may all carry the
same mutation. To begin to elucidate the underlying
mechanisms it was necessary to assess the mRNA levels
of mutant and wild-type p53 in individual cells. Thus we
developed a novel method to detect specific p53
mutations in tissue sections by performing in situ
polymerase chain reaction (PCR) on a glass slide,
selectively amplifying the DNA fragments of interest
(Hasse et al., 1990; Martı´nez et al., 1995). The selection
of primers was based on the two base-pair mismatch
method (Cha et al., 1992). We also applied in situ reverse
transcription (RT) – PCR to detect mutant mRNAs of
p53. The reaction of in situ RT–PCR using mutant
specific primers would be able to reveal both mutant
cDNA fragments amplified within the cytoplasm and
mutant DNA fragments amplified within the nucleus in a
single tumor cell at the same time.
These techniques allowed us to visualize the same p53
mutation in all tumor cells, while the levels of mutant
mRNA were variable. Moreover, there was a correla-
tion between the expression of mutant mRNA and
immunohistochemical staining for p53. Our findings
support the concept that heterogeneous distribution
patterns of p53 immunoreactivity in NSCLCs resulted
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from regulation of mutant p53 expression rather than
genotypic dierences in tumor cells.
Results and Discussion
Diffuse pattern of p53 overexpression and a point
mutation
The specimen (Case 1) was a right lower lobe lung
mass from a 55-year-old 30 pack year smoker.
Histologically it was a poorly dierentiated NSCLC
which by immunohistochemistry revealed low level of
diusely distributed nuclear staining indicating p53
overexpression in most of the tumor cells. No Mdm2
expression was detected. A point mutation at codon 47
of p53 (CCG to TCG) was identified by DNA
sequencing of the microdissected material (Figure 1a).
This coincided with the mutation of the cell line NCI –
H1373 which was established from the pericardial fluid
of the same patient 18 months after the resection of the
primary lung cancer. We selected an optimal PCR
condition for each tumor with its individually designed
primers including mutant specific (Muts, Figure 2a),
wild-type specific (WTs), common (Com) primers, and
omission of primers (0).
In situ PCR of the NCI –H1373 cell pellet, using Muts
primers, demonstrated specific nuclear staining in over
90% cells (Figure 3a), whereas less than 1% faintly
positive cells were seen in NCI –H460, which has a wild-
type p53 gene, by these primers even after 35 cycles of
PCR. As expected, when Wts primers were used, NCI –
H1373 cells were negative (Figure 3b), while NCI –H460
were intensely positive. In the Case 1 tumor specimen,
all tumor cells were amplified by in situ PCR with the
Muts primers (Figure 3d). The amplicons obtained with
Muts primers were confirmed by Southern blotting (88
base-pairs, Figure 3c). No tumor cells were positive with
WTs primers although non-malignant cells, such as
alveolar cells or macrophages in the normal appearing
lung tissue surrounding the tumor were positive with
this set of primers (Figure 3e). As a positive control, in
situ PCR using common (Com) primers revealed that all
nuclei of both tumor and nonneoplastic cells were
reactive (Figure 3f). When primers were omitted, as a
negative control, most of the nuclei on the section
remained negative, with the exception of rare cells
conceivably undergoing apoptosis or DNA repair which
were positive (Figure 3g). Scattered cells among
unremarkable bronchiolar epithelial cells which showed
p53 overexpression by immunohistochemistry (Figure
3h), were also positive with Muts primers (Figure 3i).
These cells were too few for us to resolve if they
represented tumor cells from the near-by focus of tumor
or potentially premalignant airway epithelial cells.
The reactions by the four sets of individually
designed primers for each mutation do not only yield
specificity, but potentially address the question whether
a single p53-mutant cell reveals a loss of heterozygosity
(LOH). The Case 1 tumor specimen indicated the
presence of only mutant p53, because no amplification
was observed with wild-type specific primers in tumors.
The ability to document LOH at the cellular level is
another potentially important application.
Peripheral distribution of the p53 overexpressing tumor
cells and a point mutation
Case 2 tumor specimen was obtained from a right lower
lobe tumor mass of a 66-year-old patient with severe
chronic pulmonary emphysema. Histologically, it was a
moderately dierentiated papillary adenocarcinoma
which demonstrated focal p53 overexpression by
immunohistochemistry, composed of strongly stained
nuclei distributed over the peripheral areas of the
tumor, while most of the tumor cells were positive for
proliferating cell nuclear antigen (PCNA) (Figure 4a).
No Mdm2 expression was found in tumor cells. DNA
sequencing revealed a point mutation of p53 at codon
277, TGT to TTT (Figure 1b). While the tumor cells
Figure 1 p53 mutations in the three non-small cell lung cancer tumors examined in this study. (a) Case 1, a squamous cell
carcinoma, had one point mutation at codon 47 (proline to serine). (b) Case 2, an adenocarcinoma, had a point mutation at codon
277 (cystein to phenylalanine). (c) Case 3, a carcinoid, had a nine base-pair insertion in exon 5. WT; wild-type p53. Mut; mutant p53
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overexpressing p53 protein by immunohistochemistry in
Case 2 were seen only in the periphery of the tumor, by
in situ PCR all tumor cell nuclei were intensely stained
after PCR amplification with Muts primers (Figures 2d
and 4b), suggesting that all tumor cells carried the
mutation. With WTs primers (Figure 2d), on the
contrary, strong reaction was seen only in the nuclei
of the normal cells surrounding the tumor (Figure 4c).
Moreover, using in situ RT–PCR, cDNA fragments
which were reverse transcribed from the mutant p53
mRNA were amplified specifically with the Muts
cDNA primers (sense in exon 7; 5’-GGCCCATCCT-
CACCATCA-3’ and antisense in exon 8; 5’-
TGCGCCGGTCTCTCCCAGGGAAC-3’) resulting in
cytoplasmic staining indicating the presence of this
specific p53 point mutation at the mRNA level (Figure
4d). The signal was detected exclusively in the
periphery of the tumor coinciding with the distribution
of p53 protein-positive nuclei by immunohistochem-
istry. Interestingly, our in situ RT–PCR without
DNase treatment clearly revealed both mutant DNA
in the nuclei and mutant cDNA in the cytoplasm of the
appropriate cells (Figure 4d). The tumor cells without
overexpression of p53 revealed mutant p53 without
detectable mutant p53 mRNA by in situ RT–PCR
using Muts primers (Figure 4e).
Our current data support calling tumors positive for
p53 when there is only focal overexpression of p53
staining, and, moreover, these results clearly demon-
strate how immunohistochemical studies of small
biopsies may yield misleading conclusions, as staining
for p53 may be negative while molecular analysis
including in situ PCR would reveal the possible genetic
change in the negative cells. The heterogenous staining
pattern of these tumors would have been predicted to
reflect a heterogenous pattern of gene mutation. This is
clearly not the case and strongly suggests an interaction
potentially with a variety of transcription factors which
may control p53 expression (Kirch et al., 1999; Schreiber
et al., 1999). The homogenous distribution of mutations
of the p53 gene in NSCLCs does suggest that the
alteration occurred before the clonal expansion of these
tumors, which we have recently reported in adenosqua-
mous carcinoma of the lung (Kanazawa et al., 2000).
Figure 2 Schema of the specific primers for each mutation-site and standard PCR reactions by the primer sets. The primers for
wild-type specific (WTs), mutant specific (Muts), and common DNA fragments (Com) of each tumor, illustrated in schematic
drawings, and the standard PCR reactions by these primer sets are shown in a – c (Case 1), d and e (Case 2), f and g (Case 3).
Control DNA is human genomic DNA with wild-type p53. Mutant DNAs extracted from the tumor tissues were cloned and
amplified using these primer sets. The cell lines, NCI –H1373 and NCI –H727, both of which were established from the tumor
tissues of Cases 1 and 3, respectively, were also used as mutation controls. (b) The test reactions for selecting optimal PCR
conditions (2.5 mM Mg2+, pH 10.0, with an annealing temperature of 618C) for Muts primers in Case 1 are shown. W; wild-type
p53 DNA and M; mutant p53 DNA. The PCR reactions without primers were always compared as negative control (0 in c, e, and g)
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Scattered foci of p53 overexpression and a
nine base-pair duplication
Case 3 specimen was obtained from a 65-year-old, 60
pack-year smoker who underwent a surgical resection
for a right upper lobe lung mass which was found to
extend to the pleura. Histologically the tumor was an
atypical carcinoid which revealed scattered clusters of
cells with p53 positive nuclei by immunohistochemistry
(Figure 5a). The tumor was negative by Mdm2
staining. Our molecular analysis of the primary tumor
identified a nine base-pair duplication in exon 5 of the
p53 gene (Figure 1c). This abnormality was also
present in the cell line NCI –H727 derived from this
primary (Mitsudomi et al., 1992). In this case, because
designing Wts primers was impossible, only two sets of
primers were synthesized.
The Case 3 tumor, which demonstrated p53 protein
overexpression in a limited number of cells, was found
to have the same mutation (nine base-pair duplication)
throughout all the tumor cells, as indicated by
amplification with Muts primers (Figure 2f) during in
situ PCR (Figure 5b). This observation was confirmed
by PCR–SSCP, which revealed similar shifted bands
in both the p53 positive and the negative immuno-
reactive areas which were microdissected for this
analysis (Figure 5e). In non-malignant lung tissue
distant from the primary tumor, foci of Type II cell
hyperplasia revealed no p53 overexpression by im-
munohistochemistry, no reaction with mutant specific
(Muts) primers and no shifted band by PCR–SSCP,
further confirming the reliability of the mutant specific
reaction (data not shown). By in situ RT–PCR, a
variable pattern was observed consisting of dark
Figure 3 Photomicrographs of the squamous cell carcinoma (Case 1) examined by in situ PCR. In the corresponding cell-line
NCI –H1373, specific reactions are (a) positive with Muts primers, and (b) negative with Wts primers (originally 6800). Using
sections derived from the tumor (d – g) (originally680), Muts primers amplified only mutant p53 found in the tumor cells (d), which
was confirmed by Southern blot using mutant DNA fragments as a probe (c, lane 1: DNA fragments from tumor sections by in situ
PCR with Muts primers; lane 2: wild-type fragments by standard PCR as negative control; and lane 3: mutant DNA 88 bp
fragments by standard PCR as positive control). Wts primers amplified only wild-type p53 in the non-malignant cells (e, bottom).
Common primers reacted with both wild-type and mutant p53 (f), while no amplification was seen without primers (g). Several
nuclei in the lining of bronchiolar epithelium were found to have p53 mutation by in situ PCR (h, arrows, 6200). Same cells also
revealed p53 overexpression by immunohistochemistry (i, arrows; immunoperoxidase stain, 6200). t; tumor
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Figure 4 Photomicrographs of the adenocarcinoma (Case 2). (a) Double immunostaining for p53 and PCNA showed that most
tumor cells are positive for PCNA (stained in blue), while p53 overexpression (in dark and light brown) is seen only in the periphery
of the tumor (left side; immunoperoxidase stain, 6200). (b) By in situ PCR with Muts primers, all tumor-cell nuclei were positive
(6200). (c) With Wts primers reaction was limited to normal cells while large tumor cells were negative (6400). (d) The cytoplasm
of the p53 immunoreactive tumor cells was intensely positive by in situ RT–PCR for amplifying mutant cDNA fragments (6400).
Note that tumor cell nuclei were also staining because this reaction was done without digestion by DNase. (e) In contrast, tumor
cells which were negative by immunostaining revealed a minimal reactivity by in situ RT–PCR (6400)
Figure 5 Photomicrographs of the carcinoid (Case 3). (a) Focal reactivity for p53 was observed by immunohistochemistry. Note
strong nuclear staining in the center, while other groups of tumor cells remained negative (arrow heads; immunoperoxidase stain,
6400). (b) All tumor cells reveal intense positivity following amplification using mutant specific primers while the surrounding non-
malignant stromal cells are negative (6400). (c) By in situ RT–PCR, without DNA digestion, the tumor cells in the positive foci by
immunohistochemistry were significantly darker than (d) the tumor cells in the negative foci (6400). (e) By PCR–SSCP analysis,
DNA from the whole tumor (second lane from left), demonstrated a shift indicating the presence of a mutation, which is identical to
the shifts in the DNA extracted from immunohistochemically positive (third lane from the left) as well as negative area (fourth lane
from the left) and confirmed by the shifted band of cloned (mutant) DNA
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cytoplasmic reactivity corresponding to the areas of
p53 protein overexpression areas (Figure 5c,d).
Recent studies from multiple laboratories have
demonstrated posttranslational mechanisms by which
the wild-type p53 protein half life is extended including
through Mdm2 interactions and possible phosphoryla-
tion (Prives, 1998). This leads to a disproportionate
amount of p53 protein when compared to mRNA.
Thus, it could be anticipated that one should find
tumors with p53 immunoreactivity, low amounts of
mRNA and a wild-type gene. Indeed, the pattern of
p53 immunoreactivity could be heterogenous as the
abnormalities such as hypoxia, or genotoxic stress may
be present only in certain areas of the tumor. However,
we examined tumors which displayed mutant p53
which by the virtue of its mutation has an extended
protein half life. Our approach using RT–PCR may
also help resolve discrepancies between the immuno-
histochemical studies and molecular analyses of p53 in
human lung cancers using whole tumor DNA or
mRNA (Brambilla et al., 1993).
In summary, we describe an assay to examine the
consequences of p53 mutations for gene expression in
lung carcinogenesis at the cellular level. The somewhat
unexpected finding of a correlation of the mutant p53
mRNA and protein expression in tumor cells under-
scores the importance of novel complementary techni-
ques that may extend beyond microdissection (Park et
al., 1999). Potential applications of in situ methods
include genetic analyses in many clinical settings
employing existing, archival material (Nuovo et al.,
1999).
Materials and methods
Tumors and cell lines
Surgically resected specimens of the primary NSCLC tumors
(Cases 1 – 3) and corresponding lung cancer cell lines NCI –
H1373 and NCI –H727 were part of a prospective clinical
trial of the patients with any stage or histologic subtype of
pathologically confirmed NSCLC with an Eastern Coopera-
tive Oncology Group performance status of three or better
(at least partially ambulatory) who were entered into the
study at the NCI –Navy Medical Oncology Branch as
previously described (Shaw et al., 1996). In addition, we
used a well characterized NCI –H460 lung cancer cell line
(NCI –Navy Medical Oncology Branch, Bethesda, MD,
USA) as a control for wild-type p53 (Takahashi et al.,
1989). All material used in the current study was derived
from investigations which were performed after approval by
local institutional review boards.
Tumor specimens were fixed with 10% formalin and
embedded in paran according to routine procedures. To
simulate the conditions of tumor specimens, pellets of freshly
grown cell lines were fixed for 2 h in 4% paraformaldehyde,
washed in PBS, resuspended in 1 ml of 2% NuSieve low
melting-point agarose (NuSieveR, FMC BioProducts, Rock-
land, ME, USA), allowed to solidify and embedded in
paran (Takahashi et al., 1989). Sections from the paran-
embedded cell pellets were used to test the specificity of in
situ PCR reactions.
Immunohistochemistry
Following antigen retrieval, p53 immunostaining was per-
formed using the mouse monoclonal antibody DO-7 against
human p53 (Dako Corporation, Carpinteria, CA, USA) at
4.8 mg/ml, and avidin-biotinylated peroxidase method with
Vectastain kit (Vector Laboratories, Burlingame, CA, USA)
as previously described (Ebina et al., 1994). Double staining
for p53 and PCNA was also performed using an antibody
against p53 in 9.5 mg/ml and PCNA, PC10 (monoclonal
mouse antibody; Dako Corporation) in the concentration of
19.3 mg/ml, according to our previous study (Ebina et al.,
1994). For Mdm2 detection we used a mouse monoclonal
antibody against the human protein from Oncogene Science
(Cambridge, MA, USA) at dilution 10 mg/ml. Optimal
concentrations for each antibody were determined by pilot
studies using known positive control sections (Hall et al.,
1997).
Microdissection and DNA extraction
From serially cut, dewaxed and dried sections, tumor foci
corresponding to p53 positive or negative areas by
immunohistochemistry, were microdissected using micropipet
tips and collected into separate tubes. Specimens were
digested with 0.5 ml of protein lysis buer (50 mM Tris,
1 mM EDTA, 0.5% Tween 20, pH 8.5) containing 0.4 mg/ml
proteinase K, for 3 h at 558C. The reaction was stopped by
heating at 948C for 7 min. In addition, genomic DNA was
extracted from freshly grown cell lines to be used in the
standard PCR.
PCR/SSCP analysis and DNA sequencing
A Perkin-Elmer 9600 Thermocycler (Perkin-Elmer Cetus,
Norwalk, CT, USA) was used to amplify the DNA samples.
The DNA extracted from the various tumor areas was used
for PCR/single-strand conformation polymorphism (SSCP)
analysis spanning p53 exons 4 through 9 (Mitsudomi et al.,
1992; Hall et al., 1997). The exons showing shifted bands
were cloned into a pCRII vector (Invitrogen, San Diego, CA,
USA), and purified through Qiagen Mini Columns (Qiagen
Inc., Chatsworth, CA, USA). DNA sequencing was per-
formed using a dsDNA cycle sequencing system (Gibco –
BRL, Gaithersburg, MD, USA) and primers end-labeled with
g-33P-ATP (Amersham Corp., Arlington Heights, IL, USA)
(Figure 1).
Design of the primers and testing them in standard PCR
Following the double mismatch approach (Cha et al., 1992),
we designed three to six pairs of mutant specific primers
(Muts) for the cases with single base-pair mutations in p53,
resulting in one base-pair mismatch with mutant p53 and two
base-pair mismatches with wild-type. Likewise, specific
primers for wild-type p53 (Wts) were synthesized which had
one base-pair mismatch with wild-type and two base-pair
mismatches with the mutant p53. Common primers (Com)
had no mismatch with wild-type, but one base-pair mismatch
with mutant p53, and, consequently, amplified both wild and
mutant p53.
In the first case (Figure 1a) the sense primer of Muts was
set within intron 3 (11999 – 12020; 5’-TGCTCTTTTCACC-
CATCTACAG-3’) while the antisense primer (5’-GAAC-
CATTGTTCAATATCGTCCAA-3’) was set to detect the
mutation (TCG) in codon 47. They had one base-pair
mismatch with mutant p53 and two base-pair mismatch with
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wild-type p53. The wild-type specific (WTs) primers set
within exon 4 (sense; 5’-GATGATTTGATGCTGTCCT-3’,
antisense; 5’-CAGGGGCCGCCGGTGTAGGAG-3’), which
had one base-pair mismatch with wild-type p53 and two
base-pair mismatch with mutant p53 were designed for
detecting exclusively the wild-type (CCG) sequence (Figure
2a). Common (Com) primers set in intron 3 (sense; 5’-
TGCTCTTTTCACCCATCTACAG-3’) and in exon 4 (anti-
sense; 5’-GAACCATTGTTCAATATCGTCCGG-3’), were
set as a positive control, with no mismatch with wild p53
and one base-pair mismatch with the mutant p53 (Figure 2a).
The optimal PCR condition for each primer set was tested as
shown in Figure 2b. The optimal PCR-mixture composition
selected for these three dierent pairs of primers (WTs, Muts,
and Com) was 2.5 mM Mg2+, pH 10.0, with an annealing
temperature of 618C. The sizes of the products were 136 base-
pairs by Wts, and 88 base-pairs by Muts primers (Figure 2c).
In the second case (Figure 1b) the wild-type specific
primers (Wts, sense in exon 8; 5’-GAGGTGCGTGTTTGTG-
CCCG-3’ and antisense in intron 9; 5’-CAGGGGCCGCCG-
GTGTAGGAG-3’) amplified their specific target sequences
yielding a 133 base-pair product (Figure 2d). The sense
primer of the mutant specific (Muts), and common (Com)
primers was set in intron 7 (14424 – 14447, 5’-CTTGCTTCT-
CTTTTCCTATCCTGA-3’), and antisense primers were set
in exon 8 with the dierent sequence at the end of three
prime (Muts; 5’-TGCGCCGGTCTCTCCCAGGGAAC-3’
and 5’-TGCGCCGGTCTCTCCCAGGGACA-3’) (Figure
2d). The optimal reaction required a PCR mixture containing
1.5 mM Mg2+ at pH 10.0, and an annealing temperature of
608C (Figure 2e).
As the third case was found to have a nine base-pair
duplication in exon 5 (Figure 1c), only two sets of primers
were designed: (i) mutant specific primers (Muts), for
amplifying mutant p53 only and (ii) common primers
(Com) which amplified both wild and mutant p53. As shown
in Figure 2f, both sense and antisense primers of Muts were
set within exon 5 (5’-TACTCCCCTGCCCTCAAC-3’ and 5’-
CTGTGACTGCTTGTACTG-3’, respectively), which were
also used to amplify mutant cDNA during in situ RT–PCR.
The common primers (Com) were also set within exon 5
(sense; 5’-CGCGCCATGGCCATCTACAAG-3’, antisense;
5’-CTCATGGTGGGGGCAGCGCCT-3’), and the PCR
products were 69 bp in wild-type p53 and 78 bp in this
mutant p53 sequence with nine base-pair duplication.
Standard PCR with these primers demonstrated their
specificity by yielding 69 and 78 bp products for the Com
and Muts primers, respectively (Figure 2g). Optimal PCR
conditions were 1.5 mM Mg2+, pH 10.0 and an annealing
temperature of 608C.
All primers were synthesized in-house using a MilliGen
8700 DNA synthesizer (Millipore, Marlborough, MA, USA).
As indicated, the specificity of the designed primers was
tested by standard PCR, using human genomic DNA, DNA
extracted from cell lines, or cloned DNA fragments. The
MgCl2 concentration and pH of the PCR mixture was
selected using PCR Optimizer Kit (Invitrogen, San Diego,
CA, USA). The appropriate annealing temperature was
selected from a range between 51 and 638C and settled for
each set of primers to avoid the possible eect by dierent
annealing temperature (Figure 2b). The other conditions were
kept identical for all reactions in the three tumors:
denaturing at 948C for 15 s, annealing time for 30 s and
extension at 728C for 30 s for 30 cycles, with an initial
denaturing step at 948C for 1 m. In order to perform ‘hot
start’ in our PCR reaction (Nuovo, 1994), we applied the
neutralizing antibody technique (Martı´nez et al., 1995) using
TaqStart antibody (Clontech Laboratories, Palo Alto, CA,
USA).
In situ PCR
Direct in situ PCR was performed as previously described
with minor modifications (Martı´nez et al., 1995). Briefly,
dried dewaxed sections on DNaseRNase free glass slides were
incubated with protein lysis buer (0.1 M Tris, 50 mM
EDTA, pH 8) containing 20 mg/ml Proteinase K for 20 min
at 378C. The reaction was stopped with PBS containing 0.1 M
glycine for 5 min. After thoroughly washing with PBS, 75 ml
of the PCR optimal solution of, containing digoxigenin-11-
[2’-deoxy-uridine-5’]-triphosphate (DIG-11-dUTP; Boehringer
Mannheim, Indianapolis, IN, USA) was added and the PCR
reaction was carried out for 20 – 35 cycles in an Omni Slide
System thermocycler (Hybaid, Hollobrook, NJ, USA). After
washing twice in 0.16SSC for 20 min each at 458C, the
incorporated PCR fragments were visualized by the digox-
igenin detection kit (Boehringer Mannheim).
In situ RT–PCR
After Proteinase K (10 mg/ml) digestion at 378C for 15 min,
reverse transcription was performed using the SuperScript
Preamplification System (Gibco –BRL) following the manu-
facturer’s specifications. In brief, 70 ml DEPC-treated water
containing 2.5 mg oligo(dT)12 – 18 was added to each section,
covered with parafilm, and incubated for 10 min at 708C.
After 1 min on ice, another solution (30 ml) including reverse
transcriptase (100 U/section) was added to the sections,
covered with parafilm, and the slides were incubated at
428C for 50 min, followed by 15 min at 708C. After thorough
washes, direct in situ PCR was performed after this reverse
transcription reaction using mutation specific primers as
described before.
Controls included substituting the primers by H2O in the
PCR reaction and omission of the reverse transcription in the
case of mRNA.
Southern blotting analysis
After in situ PCR using mutant specific primers without DIG-
11-dUTP, whole sections were scraped from the slide into
tubes, and amplified DNA fragments were extracted by
ethanol precipitation and loaded onto a 2% agarose gel. The
separated fragments were transferred to nitrocellulose
membranes, Nytran Plus (Schleicher & Schnell, Keene, NH,
USA), hybridized with the probes, corresponding to the
mutant DNAs labeled with a-32P-dCTP using Prime It
(Strategene, La Jolla, CA, USA).
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